Literature DB >> 28338214

Light therapies for acne: abridged Cochrane systematic review including GRADE assessments.

J Barbaric1, R Abbott2, P Posadzki3, M Car4, L H Gunn5, A M Layton6, A Majeed4, J Car3,4.   

Abstract

We undertook a Cochrane review of randomized controlled trials (RCTs) evaluating the effects of light-based interventions for acne vulgaris. We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, ISI Web of Science and grey literature sources (September 2015). We used the Grading of Recommendations Assessment, Development and Evaluation Working Group approach to assess the quality of evidence (QoE). We included 71 RCTs (4211 participants, median sample size 31). Results from a single study (n = 266, low QoE) showed little or no difference in effectiveness on participants' assessment of improvement between 20% aminolaevulinic acid (ALA) photodynamic therapy (PDT), activated by blue light, vs. vehicle plus blue light, whereas another study (n = 180) comparing ALA-PDT (red light) concentrations showed that 20% ALA-PDT was no more effective than 15% ALA-PDT but better than 10% and 5% ALA-PDT. Pooled data from three studies (n = 360, moderate QoE) showed that methyl aminolaevulinate PDT, activated by red light, had a similar effect on changes in lesion counts vs. placebo cream with red light. Several studies compared yellow light with placebo or no treatment, infrared light with no treatment, gold microparticle suspension with vehicle and clindamycin/benzoyl peroxide (C/BPO) combined with pulsed dye laser with C/BPO alone. None of these showed any clinically significant effects. Most studies reported adverse effects, but inadequately, with scarring reported as absent, and blistering only in studies on intense pulsed light, infrared light and PDT (very low QoE). Carefully planned studies, using standardized outcome measures and common acne treatments as comparators, are needed.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28338214     DOI: 10.1111/bjd.15495

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  [Light-based inflammatory acne treatments].

Authors:  C Salavastru; G S Tiplica; D E Branisteanu; K Fritz
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 2.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

3.  Visually augmented targeted combination light therapy for acne vulgaris: a case report.

Authors:  Alireza Yazdi; Colin-William Lyons; Niamh Roberts
Journal:  J Med Case Rep       Date:  2017-10-31

Review 4.  Adult female acne: a guide to clinical practice.

Authors:  Maria Cecilia Rivitti Machado; Edileia Bagatin; Thais Helena Proença de Freitas; Maria Cecília Rivitti-Machado; Beatriz Medeiros Ribeiro; Samanta Nunes; Marco Alexandre Dias da Rocha
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

5.  Comparative Study Of Photodynamic Therapy With Riboflavin-Tryptophan Gel And 13% 5-Aminolevulinic Acid In The Treatment Of Mild To Moderate Acne Vulgaris.

Authors:  Suparat Wangsuwan; Jitlada Meephansan
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-11-05

Review 6.  Dermatology: how to manage acne vulgaris.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2021-10-11

Review 7.  Menopausal Acne - Challenges And Solutions.

Authors:  Niti Khunger; Krati Mehrotra
Journal:  Int J Womens Health       Date:  2019-10-29

8.  Fluorescent light energy combined with systemic isotretinoin: A 52-week follow-up evaluating efficacy and safety in treatment of moderate-severe acne.

Authors:  Antonio Russo; Maiken Mellergaard; Giovanni Pellacani; Steven Nisticò; Michael Canova Engelbrecht Nielsen
Journal:  Clin Case Rep       Date:  2021-02-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.